中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2013年
1期
101
,共1页
乙型肝炎%慢性%肝纤维化%黄芩苷%替比夫定
乙型肝炎%慢性%肝纖維化%黃芩苷%替比伕定
을형간염%만성%간섬유화%황금감%체비부정
Hepatitis b%Chronic%Liver fibrosis%Baicalin%Telbivudine
目的:探讨黄芩苷联合替比夫定治疗慢性乙肝早期肝硬化的临床疗效及安全性.方法:将140例慢性乙型肝炎早期肝硬化患者随机分为观察组和对照组各70例,对照组采用替比夫定治疗,观察组同时给予黄芩苷治疗.结果:治疗后两组患者的ALT、AST、TBiL等肝功能指标以及HA、LN、PC-Ⅲ等肝纤维化指标与治疗前比较,有显著性差异(P<0.01),组间比较有显著性差异(P<0.05).结论:黄芩苷联合替比夫定治疗慢性乙肝早期肝硬化,能更好地改善患者的肝功能,值得临床推广.
目的:探討黃芩苷聯閤替比伕定治療慢性乙肝早期肝硬化的臨床療效及安全性.方法:將140例慢性乙型肝炎早期肝硬化患者隨機分為觀察組和對照組各70例,對照組採用替比伕定治療,觀察組同時給予黃芩苷治療.結果:治療後兩組患者的ALT、AST、TBiL等肝功能指標以及HA、LN、PC-Ⅲ等肝纖維化指標與治療前比較,有顯著性差異(P<0.01),組間比較有顯著性差異(P<0.05).結論:黃芩苷聯閤替比伕定治療慢性乙肝早期肝硬化,能更好地改善患者的肝功能,值得臨床推廣.
목적:탐토황금감연합체비부정치료만성을간조기간경화적림상료효급안전성.방법:장140례만성을형간염조기간경화환자수궤분위관찰조화대조조각70례,대조조채용체비부정치료,관찰조동시급여황금감치료.결과:치료후량조환자적ALT、AST、TBiL등간공능지표이급HA、LN、PC-Ⅲ등간섬유화지표여치료전비교,유현저성차이(P<0.01),조간비교유현저성차이(P<0.05).결론:황금감연합체비부정치료만성을간조기간경화,능경호지개선환자적간공능,치득림상추엄.
Objective:Discussion of baicalin combined in the treatment of chronic hepatitis B liver cirrhosis clinical curative effect and safety.Methods:140 cases of chronic hepatitis B liver cirrhosis patients were randomly divided into the observation group and the control group with 70 cases in each group, the control group used in treatment, the observation group while giving the baicalin treatment.Results:After treatment in two groups of patients with ALT, AST, TBiL and other indexes of liver function and HA, LN, PC- Ⅲand other indexes of hepatic fibrosis as compared with before treatment, there were significant differences between the groups (P<0.01), there was significant difference (P<0.05).Conclusion:Baicalin combined in the treatment of chronic hepatitis B liver cirrhosis, can improve the patient’s liver function, worthy of clinical application.
